Bayer's Analyst Camp Splits Wide Open as September Court Date Looms Over a Strong Quarter

Bayer shares rise as Goldman, JPMorgan, UBS, Deutsche Bank raise targets to €60-63.50, while Jefferies holds at €46 amid legal overhang.

The gap between Wall Street's most bullish and most cautious voices on Bayer has rarely been this pronounced. Within the span of 24 hours, the Leverkusen-based conglomerate received a flurry of upgraded price targets from four major investment banks — and a starkly more conservative verdict from another — leaving investors to weigh a solid operational quarter against a legal overhang that refuses to clear.

Goldman Sachs, JPMorgan, UBS and Deutsche Bank Research all moved their targets for the German pharmaceutical and agrochemical group on Thursday, with price objectives ranging from 60 to 63.50 euros. Goldman led the pack with an upgraded target of 63.50 euros and a "Buy" rating, while JPMorgan settled on 61 euros with an "Overweight" call. UBS set its sights at 62 euros, maintaining "Buy," and Deutsche Bank Research confirmed its own "Buy" recommendation with a 60-euro target. The DZ Bank, which had weighed in a day earlier, also lifted its fair value from 54 to 60 euros with a "Kaufen" rating.

Shares responded modestly, trading at 48.31 euros on Thursday, up 0.4 percent. That followed a 2.1 percent dip to 48.14 euros the previous session — a pullback that came even as the DZ Bank and Jefferies delivered their conflicting assessments on the same day.

A Quarter That Shifted the Narrative

The catalyst behind the analyst enthusiasm is Bayer's second-quarter 2026 results, published on August 4. The company beat market expectations by a comfortable margin, powered by a robust agricultural division and cost-cutting measures that have begun to show up in the numbers. The pharma segment also contributed, with sales of newer medications climbing noticeably during the period.

CEO Anderson used the earnings release to reaffirm the company's full-year 2026 guidance, describing the business as "operationally on track" and making clear that strategic priorities were advancing. He also poured cold water on speculation about a breakup or sweeping restructuring, stating that Bayer intends to keep its current structure for the time being and focus on operational improvements.

That message has resonated with the more optimistic analysts, who see the stock trading roughly 10 percent below its 52-week high of 53.86 euros, reached in early July. The new batch of price targets sits comfortably above that previous peak — a signal that the bulls believe the operational story has room to run.

The Skeptic's View

Jefferies, however, is not convinced. The bank kept its "Hold" rating and a 46-euro price target on August 10 — a level that sits below the current share price and stands in stark contrast to the 60-euro-plus targets from its peers. The firm's caution appears rooted in the same legal uncertainty that has dogged Bayer for years, rather than any deterioration in the underlying business.

The divergence has created an unusually wide valuation gap between the optimists and the skeptics. With a market capitalization of 48.36 billion euros, the stock still trades roughly 20 percent above its 200-day moving average despite the recent giveback. Technical indicators suggest a consolidation phase rather than a decisive breakout or breakdown: the relative strength index sits at 52.7, pointing to neither overbought nor oversold conditions, while annualized volatility of 26 percent underscores the nervousness surrounding the name.

The September Hurdle

At the heart of the disagreement is the unresolved glyphosate litigation. A US court has pushed back the hearing on Bayer's proposed $7.25 billion Roundup settlement to September 14, following a request from the company itself for a brief postponement. Until that date passes, the legal overhang will continue to color both the share price and the debate between bullish and bearish analysts.

The stock's recent trajectory tells the story of a market caught between two forces: the operational progress that has driven the rally over recent weeks, and the legal calendar that keeps extending the period of uncertainty. The shares have given back roughly 2.5 percent since their post-earnings surge, a modest retreat that some read as profit-taking and others as the beginning of a more sustained consolidation.

What happens next likely hinges on that September court date. If the settlement receives judicial approval, the 46-to-60-euro target range could narrow quickly as the bears lose their primary argument for caution. If it slips again or encounters fresh obstacles, the bulls may find their operational thesis tested against a legal reality that shows no signs of fading. For now, investors are left to navigate a stock where the fundamental story has improved but the risk profile remains stubbornly intact.